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evidence were extracted. Results: Our search identified 19 submissions, all of 
which included a placebo-controlled trial, and all except dimethyl fumarate also 
included a head-to-head trial against one of the beta-interferons but not any other 
therapies. Indirect comparisons against old and newer DMTs were also included 
in the submissions. Approximately 90% of appraisals received positive recom-
mendations; reasons for positive recommendations included recognition that 
there is a need for additional treatment options in MS, particularly for patients 
who do not have an adequate response to beta-interferons, and that oral DMTs 
represent an innovative step in the treatment of MS. However, submissions were 
generally criticised for trial design, scarcity of head-to-head trials, use of EDSS 
to measure disability, the uncertainty regarding long-term clinical and economic 
outcomes, and the heterogeneity of trial populations included in indirect compari-
sons. ConClusions: Due to the changing treatment landscape and the popula-
tion included in MS trials, it is clear that placebo-controlled trials and the inclusion 
of beta-interferon trials in indirect comparisons are becoming less suitable for the 
evaluation of new MS treatments. Future HTA submissions will need to take into 
account the need to demonstrate superiority over comparators, and manufactur-
ers and regulators will need to work together to develop new and reliable measures 
that can evaluate MS symptoms and impairments in the context of DMTs.
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objeCtives: Health technology assessment and decision making process lean 
on evidences provided by RCTs. Our aim was to compare the characteristics of 
Hungarian patients with multiple sclerosis to the participants enrolled in pivotal 
trials of first-line DMTs. Methods: The database of the National Health Insurance 
Fund was used for analyze the attributes of all MS patients starting first-line DMTs 
between 2008 and 2013. We investigated the following characteristics: 1. age, 2. 
gender ratio, 3. time since first MS symptoms, 4. time since first MS diagnosis, 
5. number of relapses in 2 years prior to therapy. For the comparison we summarized 
phase III RCTs of interferon beta-1a and 1b, glatiramer-acetate, teriflunomide and 
dimethyl-fumarate. Results: A total of 3877 Hungarian MS patients were involved 
and 1670 were selected for analysis after excluding the population of the year of 
DMT inclusion. The mean age was 36.18±9.96 years which resembles to the par-
ticipants of old immunomodulatory drugs (≈36 years) and slightly younger than 
the patients of the trials with new therapies (≈38 years). There was no difference 
in gender ratio (≈70% female). While in the RCTs the mean time since first symp-
toms was longer than the mean time since first diagnosis (≈7–8 vs ≈5.5 years), in 
the Hungarian patients these two values did not differ significantly (3.30±3.80 vs 
3.17±3.77 years). We suspect that the reason for this unexpected difference can be 
explained by the imprecise use of ICD codes in Hungarian clinical practice. The 
relapse rate per 2 years seemed to decline in trials of the last two decades from 3 to 
2-2.5 which is equal to the Hungarian patients. ConClusions: The population of 
RCTs represents the Hungarian MS patients in certain aspects but not completely. 
Our analysis can help the adaptation of international models to local circumstances 
in HTA of forthcoming MS therapies.
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objeCtives: Disease Modifying Treatments (DMTs) to manage Relapsing Remitting 
Multiple Sclerosis (RRMS) patients have traditionally been injectables. With the 
introduction of new oral DMTs, a better understanding of the shift in treatment 
patterns and their impact on patient disease burden is needed. The objective of 
this study was to assess the characteristics of RRMS patients taking injectable 
and oral DMTs in the United States (US). Methods: A multi-center retrospective 
chart-review study of RRMS patients was conducted in the US in 4Q2013 to collect 
de-identified data on diagnosis, clinical status, and treatment patterns. Physicians 
were screened for duration of practice (≥ 3yrs) and patient volume (≥ 15 MS patients/
mo and recruited from a large panel to be geographically representative. Medical 
charts of the next 10 consecutive MS patients were abstracted. RRMS patients taking 
an injectable (INJ) or oral DMT were analyzed. Results: 561 eligible RRMS patients 
were included in the analysis (INJ: 66%; Oral: 34%). Patient characteristics were (INJ/
Oral): age: 41/40yrs, female: 71%/70%, time since diagnosis: 62/53mo, time between 
diagnosis and initiation of first DMT: 5/3mo, percent on first, second, and third line 
DMT were (INJ/Oral): 78%/30%, 18%/45%, and 4%/25%; time on current DMT (INJ/
Oral): 47mo/6mo. Reasons for current DMT initiation included (INJ/Oral): efficacy 
against relapses (32%/27%)/efficacy in slowing progression (24%/23%)/efficacy in 
early MS (21%/4%)/patient decision (7%/17%)/oral administration (0%/17%). Patient 
JCV status (INJ/Oral): positive-3%/23% & not tested-75%/46%; number of gadolinium-
enhanced & T2 lesions: 0.8/1.3 & 7.7/10.3; percent with ≥ 1 relapse in past 12mo: 
42%/66%; percent with Expanded Disability Status Scale score of ≥ 4.5: 15%/31%; 
percent with moderate-to-severe disability per physician judgment: 22%/40%; per-
cent with active or highly active disease per physician judgment: 37%/60%; percent 
with moderate-to-severe disease per physician judgment: 22%/44%. ConClusions: 
In this cohort of RRMS patients, physicians initiated oral DMTs predominantly as 
second or third-line treatment, and these patients may have higher disease bur-
den compared to those receiving injectable DMTs. Further research is needed to 
evaluate the observed treatment patterns and treatment sequencing strategies to 
alleviate patient burden.
(6.4%). ConClusions: These data suggest that, after initial monotherapy, a major-
ity of epilepsy treatment decisions do not follow 2012 NICE guidelines, with the 
degree of divergence increasing through lines of therapy. These results call for more 
detailed investigation into treatment patterns and the reasons for divergence from 
clinical guidelines in epilepsy.
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objeCtives: Progression of symptoms among Relapsing Remitting Multiple 
Sclerosis (RRMS) patients may necessitate active disease management. The objective 
of the study was to assess the patterns of use of tests to monitor disease activity/
progression in RRMS in EU and US, based on disease severity. Methods: A multi-
center retrospective chart-review study of MS patients was conducted in EU (UK/
France/Germany/Italy/Spain) and US to collect de-identified data on diagnosis, clini-
cal status, and disease management approaches. Health care providers (HCPs; 94% 
neurologists) were screened for duration of practice (≥ 3yrs) and patient volume (≥ 15 
MS patients/mo) and recruited from a large panel to be geographically representative 
in each country. Medical charts of next 10 consecutive MS patients were abstracted 
by each HCP. RRMS patient data was analyzed. Results: 2433 eligible RRMS patient 
charts were abstracted by 365 HCPs (EU/US: N= 265/100; mean neurology practice 
duration= 17/21yrs; mean number of patients seen per month= 66/62). In EU/US, 
patient mean age: 37/41yrs, female: 67%/70%, currently treated: 85%/88%, currently 
with mild: moderate: severe disease-60%: 34%: 5%/67%: 29%: 3%. Top-5 tests used 
to monitor RRMS varied between the regions overall as well as by patient disease 
severity (EU/US: %patients): Neurological exam: overall-83/88, mild-80/89, moder-
ate-87/86, severe-91/90; Gadolinium MRI: overall-62/71, mild-57/71, moderate-69/71, 
severe-77/70; T2 MRI: overall-62/73, mild-59/74, moderate-66/70, severe-64/75; T1 
MRI: overall-53/62, mild-51/64, moderate-55/58, severe-59/70; Expanded Disability 
Status Scale (EDSS): overall-86/29, mild-87/29, moderate-86/30, severe-80/35. 
Percent with unknown Gd-enhanced lesions were (EU/US): overall-33/40, mild-
37/42, moderate-29/37, severe-17/25. Percent with unknown T2 lesions were (EU/
US): overall-33/35, mild-34/36, moderate-32/34, severe-17/20. UK HCPs reported 
substantially more patients with unknown Gd-enhanced (70%) and T2 lesions 
(66%). ConClusions: Besides neurological exam and EDSS, MRI testing is widely 
used and its use increased with increasing disease severity (EU only); the percent 
of patients with unknown lesions decreased correspondingly. Still, one-third of 
patients had unknown lesions (with UK reporting two-thirds), warranting further 
scrutiny on practice patterns and diagnostics to optimize available therapeutic 
choices and alleviate disease burden.
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objeCtives: The aim of our study is to assess amount and frequency of the physi-
otherapy services in the different neurology diseases within out-patient care in 
Hungary. Methods: The data come from the nationwide, financial data base of 
the National Health Insurance Fund Administration covering the official reports 
of outpatient care institutes in 2009. The total numbers of different physiotherapy 
services were determined by selecting the reported specific diagnoses codes and 
counting the number treatments provided for that specific diagnosis code. The dis-
eases of the nervous system are listed in the International Classification of Diseases 
(ICD) with code of G00-G99. Results: The total number of the 151 different types 
WHO-classified physiotherapy procedures was 32318413; and 1331675 (4.12%) of 
them related to neurology care with the ICD code group G00-G99. The amount and 
frequency of the physiotherapy services are in the different neurology diseases are 
the following: Inflammatory diseases of the central nervous system 3584 (0.26%), 
Systemic atrophies primarily affecting the central nervous system 7265 (0.52%), 
Extrapyramidal and movement disorders 82923 (5.96%), Other degenerative diseases 
of the nervous system 15717 (1.13%), Demyelinating diseases of the central nervous 
system 30300 (2.18%), Episodic and paroxysmal disorders 191909 (13.80%), Nerve, 
nerve root and plexus disorders 438780 (31.56%), Polyneuropathies and other disor-
ders of the peripheral nervous system 96871 (6.97%), Diseases of myoneural junction 
and muscle 21276 (1.53%), Cerebral palsy and other paralytic syndromes 434550 
(31.26%), Other disorders of the nervous system 67024 (4.82%). ConClusions: The 
diseases of the nervous system showed different utilization frequency in physi-
otherapy services and represent a significant burden for the health care system.
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objeCtives: In recent years, a number of new DMTs for the treatment of MS 
have been approved by the FDA and EMA, specifically fingolimod, dimethyl 
fumarate, teriflunomide, and alemtuzumab. This study evaluated the HTA 
appraisals for these DMTs to identify any trends or future opportunities in 
MS. Methods: HTA appraisals for fingolimod, dimethyl fumarate, terifluno-
mide, and alemtuzumab from NICE (England), SMC (Scotland), CADTH (Canada), 
PBAC (Australia), HAS (France), TLV (Sweden) and IQWiG (Germany) were iden-
tified. Recommendations, reasoning, and the supporting clinical and economic 
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among patients. ConClusions: Based on our research among patients we con-
clude that generic substitution is most likely effective drug policy tool, but since 
there are also many negative experiences (own or shared) with generic drugs, GS is 
still considered as alternative treatment.
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objeCtives: The research analyses (i) the individual and interactive effects of 
three pharmaceutical policies (cost-sharing, prescription quotas, therapeutic ref-
erence pricing) on drugs public and private expenditure and volumes, using Italian 
regional policies as a case-study; (ii) the extent to which the long-run effect of poli-
cies on expenditure is mediated by prescribers’/patients’ behaviours. Methods: 
An enriched difference-in-differences model is used. Firstly, policies impact on 
public and private expenditure and volume is separately estimated. Then, the 
hypothesis that the effects of policies on public expenditure are mediated by behav-
iours (transmission mechanism) is tested. As robustness check, a possible reverse 
causality and feedback mechanisms is tested, by switching the mediator and the 
independent variable. Results: The analysis shows (i) that combined policies do 
not necessarily produce a higher impact than policies alone; (ii) a larger impact 
of policies in the short-run, whereas in the long-run the trend is often reversed, 
but not enough to compensate the final impact, which is usually in the expected 
direction; (iii) as for cost-sharing, that its negative impact on public expenditure is 
mainly due to a decrease in volumes than to a shift from public to private expendi-
ture. ConClusions: Despite its limitation, this study has shined a light on the 
impact of policies which are implemented in different time and places, thus cover-
ing an information gap and supporting policy-makers. Some empirical findings 
show also that pharmaceutical policies may have an unintended impact on health: 
e.g. the volumes decrease due to cost-sharing may imply patients under-treatment.
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objeCtives: There is a general consensus on the need for a stronger patient-cen-
teredness, even in HTA processes. In international comparison different ways of 
public participation (citizens, insured and patients) in the decision-making process 
are discussed and tested. The need was recognized, but not yet fully reflected in 
practice. This study describes how preferences can be taken into account in dif-
ferent decision situations and shows how methods of preference measurement/
citizens’ councils are used in an international context to support decision-making 
and understand the importance of various decision-criteria that influence these 
decisions. Methods: A systematic literature review in PubMed/Medline revealed 
95 articles and showed that methods of patients, citizens and policyholder par-
ticipation are manifold. In order to structure the international approaches further, 
international HTA-organizations worldwide were questioned via e-mail in the end of 
2013 on patients and public participation in their countries. Results: 17 out of 126 
contacted organizations answered to these questions. In general, the participation 
efforts extend from qualitative survey of patients’ needs up to the science-based 
documentaries of quantitative patient preferences. The review and the survey of 
the HTA-agencies show that internationally three mechanisms are used to involve 
the public in decision-making bodies: membership of at least one patient representative 
(e.g., Australia, France, Germany), presentation of oral/written comments from patients 
(e.g., Australia, The Netherlands, Great Britain) and the possibility to check the HTA-
reports and the corresponding draft recommendations before publication (e.g., France, 
Germany, Great Britain, New Zealand, USA). ConClusions: The role of the 
patients or citizens seems to be limited to an informal or ad-hoc basis and is mostly 
restricted to consulting activities. In order to achieve a patient-centered health 
technology assessment two ways to sharing information are relevant: the public 
needs information on medical and health policy/economic issues and decision-
maker need information on the patient perspective.
health Care use & PoliCy stuDies – Diagnosis related group
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objeCtives: Diagnosis Related Groups (DRG) like financing method was introduced 
in Hungary in 1993. In addition to DRG based reimbursement, an degressive upper 
ceiling (financial cap) was introduced for hospital reimbursement. The aim of our 
study was to investigate the financial effects of degressive financing method on 
the Hungarian DRG-based hospital financing. Methods: The data in our analysis 
were derived from the nationwide administrative dataset of the National Health 
Insurance Fund Administration (OEP), the only health care financing agency. We 
examined the period between 2011 and 2013. In 2011 and 2012 hospital activity 
over financial cap was reimbursed up to 110% by 30% of DRG base rate, while in 
2013 hospital activity over financial cap was reimbursed up to 104% by 25% of 
DRG base rate. Results: In 2011 hospital activity exceeded the financial cap by 
4.6% with a monthly variation of 1.5% - 6.6%. In 2012 hospital activity exceeded 
the financial cap by 4.2% with a monthly variation of 1.1% - 6.5%. In 2013 hos-
pital activity exceeded the financial cap by 1.9% with a monthly variation of 
1.1% - 2.6%. Between 2011 and 2013 the DRG base rate remained the same (150000 
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objeCtives: New oral Disease Modifying Treatments (DMTs) for Relapsing 
Remitting Multiple Sclerosis (RRMS) were recently introduced in the US. The 
objective of this study was to assess trends in adoption of oral DMTs among 
RRMS patients in the US. Methods: A multi-center retrospective chart-review 
study of RRMS patients was conducted in the US in 4Q2011, 4Q2012, 2Q2013, and 
4Q2013 to collect de-identified data on diagnosis, clinical status, and treatment 
patterns. Neurologists were screened for duration of practice (≥ 3yrs) and patient 
volume (≥ 15 MS patients/mo) and recruited from a large panel to be geographi-
cally representative. Medical charts of next 10 consecutive MS patients were 
abstracted by each neurologist. RRMS patients taking oral, injectable, or infusible 
DMTs were analyzed. Results: 2362 eligible RRMS patient charts were evaluated 
(4Q2011:23%, 4Q2012:25%, 2Q2013:25% & 4Q2013:26%). Use of oral DMTs increased 
four-fold (4Q2011:7%, 4Q2012:9%, 2Q2013:21% & 4Q2013:31%); use of injectable 
DMTs decreased (4Q2011:82%, 4Q2012:78%, 2Q2013:71% & 4Q2013:60%), as did 
use of infusible DMTs (4Q2011:10%, 4Q2012:12%, 2Q2013:7% & 4Q2013:8%). Across 
timeframes, 61%, 27% & 12% of patients were on 1st-line, 2nd-line, and 3rd-line or 
subsequent treatment, respectively. Among 3rd-line or subsequent patients, oral 
DMT use increased from 23% to 59%; use of injectable and infusible DMTs decreased 
from 34% to 16% and 37% to 25%, respectively. Among 2nd-line patients, oral DMT 
use increased from 10% to 46%; use of injectable and infusible DMTs decreased 
from 66% to 37% and 21% to 15%, respectively. Among 1st-line patients, oral DMT 
use increased from 3% to 16%; use of injectable DMTs decreased from 96% to 83% 
and infusible DMT use remained at 1-2%. ConClusions: Oral DMT use increased 
between 4Q2011-4Q2013, predominantly in 2nd or subsequent lines. The impact of 
this observed pattern of reserving new treatment options for later lines warrants 
scrutiny to optimize patient management and alleviate disease burden.
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health Care use & PoliCy stuDies – Consumer role in health Care
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aWareNess aND iNterest iN the uNiteD states health iNsuraNCe 
marketPlaCe
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objeCtives: To examine the level of awareness and interest in the newly setup 
Health Insurance Marketplace under Affordable Care Act in West Virginia state of 
the United States of America. Methods: Primary survey data were collected in 
July/August 2013 from a stratified sampling of West Virginians. A mail survey was 
completed by respondents in a cross-sectional study. Key variables included gen-
eral awareness of the Health Insurance Marketplace and the availability of subsi-
dies, the individual mandate, interest in using the Marketplace, and perceptions 
of respondents’ ability to qualify for financial assistance. Results: Six thousand 
surveys were mailed with a nine-page questionnaire. A total of 1,198 completed 
surveys were returned. Two months prior to launch, awareness of the Health 
Insurance Marketplace was low in WV; yet interest in the Marketplace was higher 
among those most likely to benefit—the insured and residents likely to qualify 
for financial subsidies. West Virginians reported being familiar with the individual 
mandate. ConClusions: Efforts should be increased at the federal, state, and local 
levels among government and non-government organizations to heighten aware-
ness of the Health Insurance Marketplace in WV and, particularly, the availability of 
subsidies. Many, once made aware, expressed interest in learning more.
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objeCtives: Slovakia has from December 2011 new law that defines list of mol-
ecules for mandatory generic substitution. It was one of the cost-containment 
measures applied in the same time at the field of drug policy. We provided research 
on statistically selected sample of patients in Slovakia to detect current attitude, 
knowledge and believes toward generic substitution (GS). Methods: We created 
special questionnaire for patients and distributed it in selected regions in Slovakia. 
From 600 questionaires, we evaluated 432. Questionares were distributed among 
patients visiting pharmacies in 2013/2014 and all patients were older than 20 
years. Results: There were 57% of women in our sample and only 11% from all 
patients had lower than college education. 71% of all patients were using prescrip-
tion drugs regularly and 58% of all patients were familiar with term GS. Suprisingly, 
only 16% from all patients selected co-payment as the key factor influencing their 
decision toward GS. Recommendation of GS in pharmacy or by doctor was selected 
as key factor that influenced patients in choosing GS or generic molecule (40%). 
Second most influential factor was own experience with generic (27%). Only 8% 
of patients believed that GS can decrease overall consumption of drugs. We also 
found out that 36% of patients consider GS as “risky” because of extended number 
of generics available from various unknown companies. There was also a strong 
statistical relationship between gender and positives as well as negatives of GS 
